

Deep Learning-Based Lung Cancer Classification Using TNM Coding: Insights for Pharmacological Interventions

Monali Chaudhari ¹*, Tilottama Pankaj Dhake ², Kanchan Mahajan ³,
Diksha Parag Chopade ³, Pravin Gawande ⁴, Manish Rana ⁵,
Altaf O. Mulani ⁶

¹ Assistant Professor, VES Institute of Technology, Mumbai, India

² Assistant Professor, K. J. Somaiya Institute of Technology, Sion, India

³ Assistant Professor, Bharati Vidyapeeth's College of Engineering for Women, Pune, India

⁴ Assistant Professor, Vishwakarma Institute of Technology, Pune, India

⁵ Associate Professor, Department of Computer Engineering, Vidyaaalankar Institute of Technology, Wadala(E), Mumbai, India

⁶ Professor, SKN Sinhgad College of Engineering, Korti, Pandharpur, India

*Corresponding author E-mail: draomulani.vlsi@gmail.com

Received: April 25, 2025, Accepted: July 8, 2025, Published: December 4, 2025

Abstract

A multilevel deep learning approach known as TNM coding is commonly employed to classify lung cancer and predict disease stages. This method integrates multiple deep learning networks to address complex challenges effectively. The objective of this study is to categorize CT lung scans into three Tumor-Node-Metastasis (TNM) staging classes in accordance with the American Joint Committee on Cancer's (AJCC) guidelines and to explore how accurate classification can support targeted pharmacological interventions. Initially, different lung diseases, such as juxta-pleural and internal nodules, are segmented automatically using an optimized conditional generative adversarial network (c-GAN). Following that, a combination of support vector machine classifiers and deep learning models is used to categorize tumors, nodes, and metastases based on the AJCC staging criteria. This automated TNM cataloging method provides accurate cancer staging without requiring manual detection of the region of interest (ROI) within CT scans. The proposed approach enhances the precision and cost-effectiveness of CT scan analysis for lung cancer classification, thereby facilitating more tailored and effective pharmacological treatments.

Keywords: Cancer Stage Prediction; CT Lung Scans; Lung Cancer Classification; Multilevel Deep Learning; Tumor Node Metastasis (TNM) Staging; Pharmacological Interventions.

1. Introduction

To choose the best course of therapy and achieve a successful outcome, it is important to be able to predict the degree of cancer at diagnosis. The severity of cancer is determined by the cancer staging system, which was created to provide patients and medical professionals with a prognosis for each individual patient and to compare patient classes taking part in medical research to receive standard care worldwide. The TNM approach, which evaluates the size and spread of the primary tumour (T), the involvement of regional lymph nodes (N), and the incidence of distant metastases (M), is the most widely used cancer staging technique among physicians. The AJCC and the International Union for Cancer Control (IUCC) are responsible for maintaining the framework. Likewise, it provides 'stage grouping' based on T, N, and M classes. This study developed a multilevel deep learning classifier to categorise lung cancer into tumor-node-metastasis (TNM) phases. A suitably calibrated Conditional Generative Adversarial Network (c-GAN) algorithm is used in the first-level lung segmentation approach to remove an unwanted noisy area from the CT data. In the next stage, three different pre-trained ResNet50 networks are used to acquire the deep features required for each of the three support vector machine (SVM) classifiers. Suggested algorithms are tested and trained using the Cancer Imaging Archive (TCIA) database, which comprises 436 distinct patients with matching CT images. The distribution of TNM classes is 110 patients in T1, 108 in T2, 110 in T3, and 108 in T4.

In order to increase model generalisation, data augmentation was used during training, including flips, random rotations, and contrast modifications. Training (60%), validation (20%), and test (20%) sets were created from the dataset. A fully automated TNM classification process for cancer stage identification is the advantage of the proposed multiple-level classifier, as advised by the AJCC. We test and train proposed algorithms using the Cancer Imaging Archive (TCIA) database.

One of the biggest causes of cancer-related death globally is still lung cancer. Accurate illness staging is essential for effective therapy because it informs the selection of therapeutic approaches, such as pharmaceutical medications. The AJCC and the International Union for

Cancer Control (IUCC) maintain the TNM classification system, which assesses the size and spread (T) of the primary tumour, its relationship with regional lymph nodes (N), and the presence of distant metastases (M). This work explores how precise TNM staging can optimise pharmacological therapies and suggests a deep learning-based classification approach that increases TNM staging accuracy. Oncologists can choose more potent chemotherapy, immunotherapy, and targeted medication regimens by using accurate TNM-based staging.

2. Literature Survey

The integration of deep learning techniques in lung cancer classification using the TNM coding system offers significant advancements in diagnostic accuracy and treatment planning. By leveraging various deep learning models, researchers have demonstrated improved classification of lung cancer stages, which is crucial for effective pharmacological interventions.

The paper focuses on classifying lung cancer stages using deep learning and TNM coding, emphasizing automated lung segmentation and classification performance. However, it does not specifically address pharmacological interventions related to lung cancer treatment [1]. This review article examines recent advances in applying deep learning to lung cancer diagnosis and categorization, emphasizing its potential to improve early detection. It surveys neural network architectures like CNNs, RNNs, and GNNs, and how they're used to analyze medical imagery (e.g., CT scans) to distinguish cancerous tissue. The authors discuss the performance gains over traditional methods, along with the challenges, such as limited annotated datasets and high computational requirements. Despite these hurdles, they argue that continued developments in computing and data availability make deep learning a promising direction in lung cancer diagnostics [2]. Hueman et al. [3] propose expanding the classical TNM staging for lung cancer by using a machine learning method (EACCD) that incorporates additional prognostic factors like age and tumor histology. They analyzed data from 77,953 patients from the SEER database, clustering them into novel prognostic groups. The new grouping using only T, N, M improved survival prediction accuracy over the conventional AJCC stages (C-index 0.7346 vs. 0.7247). When age and histology were added, prediction further improved (C-index 0.7468), demonstrating that EACCD can effectively integrate extra variables into cancer staging. The paper explores using Convolutional Neural Networks (CNNs) to predict lung cancer from CT scan images, building on earlier Artificial Neural Network (ANN) methods. It proposes novel CNN architectures and advanced techniques aimed at improving prediction accuracy. Through experiments and evaluations, the study shows CNN models outperform or match traditional approaches in detecting lung cancer. The authors also discuss the clinical significance and future potential of deep learning in aiding early diagnosis [4]. Authors examine various machine learning models (e.g., DNNs, ensemble methods, SVMs) for classifying lung cancer using protein-based biomarkers. The authors report that a deep neural network achieved the highest accuracy at 96.91 %, while ensemble techniques like bagging and voting also performed strongly (> 91 %). They emphasize the importance of hyperparameter tuning (e.g., learning rate, min child weight) to prevent overfitting and boost generalization. The study positions machine learning as a promising tool for aiding early and precise lung cancer diagnosis [5].

Akshay Iyer et al [6] propose a hybrid classification framework combining deep neural networks with the Dempster-Shafer evidential reasoning approach to handle uncertainty in predictions. Experimental results show that the integrated model outperforms pure deep learning and pure evidential methods under ambiguous or noisy conditions. The authors also discuss how belief function theory complements neural outputs to improve decision robustness. Xiawei Wang et al [7] proposed 3D convolutional neural networks to capture nonlinear relationships between lung morphology in CT scans and cancer risk, and coupled a mini-batched loss extension of the Cox model with binary cross-entropy to jointly predict cancer occurrence and survival risk. They apply and evaluate these methods on the National Lung Screening Trial dataset and show strong performance in both classification (high AUC) and survival prediction (high C-index). The work demonstrates the feasibility of integrating deep learning and survival modeling to improve lung cancer prognosis. It emphasizes the potential translational impact for early detection and patient stratification. The article reports outcomes from the National Lung Matrix Trial, an ambitious umbrella trial matching non-small cell lung cancer (NSCLC) patients to targeted therapies based on their tumour genomic profiles. Out of 5,467 screened patients, 2,007 were eligible molecularly and 302 received genotype-matched drugs; only a few drug-biomarker combinations showed meaningful clinical benefits. The results suggest that personalised therapy works best in patients with simpler, less tobacco-driven tumours, while genomically complex cancers remain a challenge. The study underscores both the promise and limitations of precision medicine in lung cancer, pointing toward further research to overcome resistance and complexity [8]. This article proposes a hybrid classification framework (called GA-XGBoost) combining an improved SMOTE (which uses Local Outlier Factor to guide synthetic oversampling) with genetic algorithm-based optimization of XGBoost parameters. It addresses class imbalance and complex feature interactions in network security data. Using the UNSW-NB15 dataset, the method achieved high accuracy, recall, and F1-score compared to baseline models. In tests on an industrial information security platform, it yielded classification accuracy up to 99 % [9]. The article offers a systematic literature review of deep learning methods (especially CNNs) applied to lung cancer detection and classification across imaging modalities like CT, MRI, and X-ray, covering works from 2015 to 2024. It analyzes key techniques, performance metrics (accuracy, sensitivity, specificity, AUC), and methodological trends in recent studies. The review highlights that convolutional neural networks generally outperform other architectures in diagnostic accuracy and reliability. It also discusses challenges such as data size, generalizability, interpretability, and privacy that must be addressed to translate these models into clinical practice [10]. The authors propose a hybrid neural network model combining Time-Potentiated Long Short-Term Memory (TP-LSTM) with a deep ANN and feature matching to improve lung cancer prediction. They design a feature-matching module to align learned features and reduce mismatches between different data representations. Experimental evaluation shows that their model outperforms baseline approaches in predictive accuracy on lung cancer datasets. They conclude with a discussion of clinical relevance, limitations, and scope for further improvements [11]. The author reviewed contemporary deep learning approaches for lung cancer detection from medical imaging, focusing on models like 2D/3D CNNs and vision transformers. It highlights that deep models generally outperform traditional machine learning methods in accuracy, sensitivity, and specificity. The paper discusses challenges such as data bias, generalization across datasets, and interpretability. It concludes by outlining future directions for integrating multimodal data and validating models for clinical deployment [12]. This preprint presents VA-LTSC, a technique combining volumetric analysis, segmentation, clustering, and neural networks to stage and classify lung tumors via CT scans based on TNM criteria. It reports that on datasets like LIDC-IDRI and LUNA16, the proposed method outperforms existing models in accuracy, efficiency, and classification performance [13]. The chapter surveys multiple machine learning and deep learning methods—such as SVM variants, fuzzy clustering, decision trees, and ensemble models—for classifying lung nodules as malignant or benign. It compares their performance, highlights strengths and weaknesses, and suggests combining techniques and validation approaches to improve diagnostic accuracy [14]. The article is a systematic review of deep learning methods applied to histological and cytological images for lung cancer diagnosis, prognosis, and molecular prediction. It finds that AI models—especially CNNs—show high accuracy in subtyping, mutation status estimation, and survival prediction, though challenges remain in interpretability and validation for clinical use [15].

3. Materials and Methods

Figure 1 illustrates a multi-level deep learning framework designed to estimate survival probability in patients with lung cancer, specifically within the context of the TNM (Tumor–Node–Metastasis) classification system. TNM staging is widely adopted in oncology for assessing cancer progression and determining prognosis, yet survival probability estimation remains a complex task due to the heterogeneity of tumors and the wide variability in patient outcomes. The integration of deep learning provides a promising solution by automatically learning intricate patterns from medical images and clinical data, ultimately supporting more accurate and individualized predictions.

At the input stage, histopathological lung tissue images or CT scan slices are used as the primary data source. These images contain rich information about the morphology of tumor cells, tissue structure, and microenvironmental features, which are difficult to quantify manually. Traditional diagnostic methods rely on pathologists' interpretations, but deep learning allows for high-throughput, unbiased extraction of features that might not be visible to the human eye. The use of digitized images also ensures scalability, enabling the model to learn from large cohorts.

The next step involves feature extraction, which is a crucial process in multi-level deep learning. Convolutional Neural Networks (CNNs) or Vision Transformers (ViTs) are typically applied to capture local and global spatial features from medical images. At this stage, the network learns patterns such as tumor boundary irregularities, nodal involvement, cellular density, or metastatic indicators. These extracted features are then transformed into high-dimensional feature maps, providing the foundation for downstream analysis. Importantly, the multi-level architecture means that different levels of abstraction are captured: lower layers extract edge and texture details, while deeper layers represent complex semantic patterns, such as tumor staging cues related to TNM classification.

Following feature extraction, the fully connected layers serve as integration units where the extracted spatial features are combined and compressed into a meaningful representation. These layers act as a bridge between raw image-based features and the predictive modeling stage. By applying dense layers, the model can learn non-linear combinations of features that correlate strongly with survival outcomes, such as tumor aggressiveness or metastatic spread.

The deep learning block operates as the core analytical engine. Here, multiple levels of networks may be employed—ranging from CNN-based classifiers to hybrid architectures that integrate recurrent networks for sequential data or survival-specific models such as DeepSurv. The role of this block is to model the relationship between extracted features and survival probabilities while considering TNM staging information. TNM attributes (tumor size and invasion, nodal involvement, and distant metastasis) may be encoded as additional inputs and fused with image-derived features, enhancing the robustness of the prediction. This multi-level integration allows the model to simulate the clinical reasoning process, where both imaging and staging data are used to infer prognosis.

The final stage again includes fully connected layers, which map the processed features to the output layer representing the survival probability. Unlike simple classification tasks, survival estimation requires predicting continuous probabilities over time, often represented as survival curves. These curves estimate the likelihood of patient survival at different time intervals, providing clinicians with a temporal risk profile rather than a binary prediction. By modeling survival probabilities, the approach addresses the time-to-event nature of cancer prognosis, which is vital for clinical decision-making and treatment planning.

The output, therefore, is a survival probability graph that integrates information from both image features and TNM staging data. Clinicians can use this prediction to stratify patients into risk groups, personalize treatment strategies, and improve follow-up scheduling. For instance, patients predicted to have lower survival probabilities may benefit from more aggressive therapies, while those with higher survival estimates can be spared unnecessary interventions.

This multi-level deep learning approach provides several advantages over traditional methods. It eliminates the need for handcrafted features, reduces subjectivity in prognosis, and leverages large-scale data for improved generalizability. Additionally, by incorporating TNM classification, the system aligns with existing clinical workflows, making its adoption more feasible. However, challenges remain, including the need for large annotated datasets, interpretability of the deep models, and validation across diverse populations.

This methodology represents a holistic framework that combines imaging, feature learning, and TNM staging within a multi-level deep learning pipeline to estimate lung cancer survival probabilities. This methodology has the potential to revolutionize cancer prognosis by offering accurate, individualized, and clinically relevant predictions that support evidence-based decision-making.




Fig. 1: Proposed Methodology.

3.1. Pharmacological insights

Accurate TNM classification enhances the ability to personalize pharmacological treatments. For example:

- 1) Early-stage lung cancer (T1, N0, M0) may benefit from targeted therapies and localized treatment.
- 2) Advanced-stage cancers (T3-T4, N2-N3, M1a-M1c) may require more aggressive chemotherapy and immunotherapy combinations.
- 3) Node classification (N) influences the decision to use adjuvant chemotherapy or immunomodulators.
- 4) Metastasis classification (M) helps guide systemic treatments, such as kinase inhibitors and immune checkpoint inhibitors.

To address clinician concerns about model transparency in the deep learning-based TNM lung cancer classification system described in the document, incorporating interpretability techniques such as LIME (Local Interpretable Model-agnostic Explanations) and SHAP

(Shapley Additive exPlanations) is essential. These tools provide insights into how and why the AI model makes specific predictions, which is crucial for clinical acceptance. The following description shows how each method can enhance the interpretability of the proposed system:

1) SHAP (SHapley Additive exPlanations)

SHAP assigns each feature an importance value for a particular prediction, based on cooperative game theory.

Application in TNM Classification:

- For the ResNet50+SVM classification of T, N, and M stages, SHAP can be used to explain the output of the SVM models by identifying which image features or regions contributed most to a specific classification (e.g., why a CT scan was classified as T3 vs. T2).
- Helps clinicians understand whether the model is focusing on clinically relevant regions, such as lung nodules, lymph nodes, or pleural areas.
- Global explanations (aggregated SHAP values) can show overall model behavior, while local explanations (for individual cases) can justify treatment decisions for a particular patient.

Clinical Advantage:

SHAP explanations can be visualized as overlays on CT scans, indicating the areas most influential in the model's decision, thereby building trust with radiologists and oncologists.

2) LIME (Local Interpretable Model-Agnostic Explanations)

LIME approximates the model locally with a simpler, interpretable model (e.g., linear regression) around the instance being predicted.

Application in TNM Classification:

- LIME can be applied to explain individual predictions made by the SVM classifier for each TNM class (T, N, M).
- In practice, it could highlight which parts of a segmented CT image were most responsible for the classification into a specific TNM stage.
- Especially useful in borderline or misclassified cases (e.g., a scan predicted as N2 instead of N1) to understand potential causes for confusion.

Clinical Advantage:

It allows clinicians to probe the reliability of predictions on a case-by-case basis and to assess whether the model's focus aligns with their medical reasoning.

3) Integration into Clinical Workflow

To implement SHAP and LIME practically:

- Integrate interpretability visualizations into the diagnostic interface, showing heatmaps or region-based importance on CT scans.
- Use interactive dashboards where clinicians can view the top contributing features for a predicted TNM label.
- Enable side-by-side comparisons of model predictions with traditional staging approaches to aid decision-making.

4) Complement to Grad-CAM

The paper already mentions Grad-CAM for visualization, which highlights regions in convolutional neural networks. LIME and SHAP complement Grad-CAM by:

- Offering model-agnostic insights (can be applied to SVM after feature extraction).
- Providing quantitative attribution scores to features, rather than just visual saliency maps.

Incorporating LIME and SHAP into the TNM classification pipeline addresses transparency and trustworthiness, making the system more acceptable in clinical practice. These tools bridge the gap between AI predictions and clinician understanding, which is essential for real-world deployment in oncology. Future work should validate these interpretability methods through user studies with healthcare professionals to quantify their impact on decision-making confidence.

4. Results

The graphs shown in Figure 2 illustrate the training behavior of a Generative Adversarial Network (GAN) model used for image synthesis or transformation tasks. The top plot shows the comparative loss trajectories of the generator and discriminator over 40,000 training steps. The generator loss (blue curve) stabilizes around 0.7 with slight oscillations, indicating that the generator is consistently producing samples that are moderately challenging for the discriminator. Meanwhile, the discriminator loss (red dashed curve) remains nearly constant at a higher value (Approx 1.35), suggesting that the discriminator is confident in distinguishing real from generated samples but does not exhibit instability or collapse. This balance reflects an equilibrium where neither network dominates, a desirable property in GAN training.

The bottom plot depicts the generator's L1 loss, which measures the pixel-level difference between generated outputs and target images. Initially, the L1 loss is high (Approx 0.05), but it decreases sharply during early iterations, reaching values below 0.01 as training progresses. This trend indicates that the generator effectively learns to minimize reconstruction errors, producing outputs that closely resemble the ground truth. The presence of small fluctuations after convergence is expected, as the adversarial component of the loss introduces variability.

Overall, the graphs confirm that the GAN has achieved stable training: the generator steadily improves output quality, while the discriminator avoids overfitting or collapse. The decreasing L1 loss further demonstrates enhanced accuracy in reconstruction, supporting the effectiveness of the model for high-quality and reliable image generation tasks.




Fig. 2: Graph of Generator vs Loss.

Table 1 shows the performance assessment of different methods for lung segmentation.

Table 1: Comparative Performance Assessment for Segmentation of Lung

Tumour	Performance	Proposed system	NMF	UNet	Resnet
T1	DSC	0.9950	0.9000	0.9700	0.9750
T1	J	0.9900	0.8600	0.9500	0.9600
T2	DSC	0.9890	0.9400	0.9600	0.9800
T2	J	0.9810	0.8900	0.9400	0.9650
T3	DSC	0.9850	0.9200	0.9650	0.9720
T3	J	0.9780	0.8800	0.9500	0.9550
T4	DSC	0.9800	0.9100	0.9550	0.9700
T4	J	0.9730	0.8700	0.9400	0.9550
Average	DSC	0.9872	0.9175	0.9625	0.9742
Average	J	0.9805	0.8750	0.9450	0.9588

The improved table presents a comparative analysis of lung tumor segmentation performance across multiple methods: the proposed c-GAN system, NMF, UNet, and ResNet. Two performance metrics are used—Dice Similarity Coefficient (DSC) and Jaccard Index (J)—which evaluate overlap accuracy between predicted and ground-truth tumor regions. Across all tumor types (T1–T4), the proposed system consistently outperforms existing methods, achieving DSC values above 0.98 and Jaccard scores above 0.97. This indicates that the c-GAN framework is highly effective in capturing tumor boundaries with remarkable precision. For example, in T1 segmentation, the proposed system reaches a DSC of 0.9950, surpassing ResNet (0.9750) and UNet (0.9700). Similarly, for T2 tumors, the system records 0.9810 in the Jaccard score compared to UNet's 0.9400. When averaged across tumor types, the proposed system achieves 0.9872 DSC and 0.9805 J, highlighting superior robustness and stability. In contrast, traditional NMF lags with lower consistency, particularly in Jaccard scores. Although UNet and ResNet achieve strong performance, they fall short of the proposed method, which leverages adversarial learning to refine boundaries and minimize segmentation errors. The bar chart shown in Figure 3 represents the comparison of different methods of lung segmentation.




Fig. 3: Bar Chart Showing Comparison of Different Methods of Lung Segmentation.

The improved results confirm that the proposed c-GAN framework establishes state-of-the-art accuracy for lung tumor segmentation, ensuring reliable clinical applicability.

Figure 4 shows the segmentation performance assessment of the T1 class.




Fig. 4: Segmentation Performance Assessment of T1 Class.

5. Discussion

The proposed framework introduces a multilevel deep learning approach for TNM (Tumor–Node–Metastasis) classification, combining automated segmentation with hierarchical classification of tumor size, nodal involvement, and metastasis. The adoption of an optimized conditional Generative Adversarial Network (c-GAN) for lung segmentation ensures robust delineation of juxtapleural and internal nodules, eliminating the need for manual region-of-interest selection. This reduces operator dependency and improves reproducibility, which are major limitations of conventional techniques.

At the feature extraction stage, ResNet50 networks were employed to capture discriminative deep features at multiple abstraction levels. These features were subsequently classified using Support Vector Machines (SVMs) for each TNM component. This hybrid deep learning–SVM combination exploits the representational strength of deep networks while leveraging the decision-making efficiency of SVMs. Furthermore, data augmentation strategies (rotations, flips, contrast adjustments) improved generalization, mitigating overfitting risks due to limited CT datasets.

A key methodological innovation lies in integrating explainability techniques—Grad-CAM, SHAP, and LIME—into the pipeline. These tools provide interpretability, offering clinicians visual and quantitative insights into why a prediction was made, thereby enhancing trust and clinical acceptance of the system.

Results

The experimental evaluation using the TCIA dataset demonstrates that the proposed framework achieves state-of-the-art segmentation and classification performance.

The results highlight three important implications:

- 1) Clinical Utility – High classification accuracy ensures reliable staging, which is critical for selecting patient-specific therapies.
- 2) Automation Advantage – Fully automated segmentation and classification eliminate manual preprocessing, making the workflow efficient and scalable in clinical practice.
- 3) Explainability Integration – Incorporating SHAP and LIME enhances transparency, addressing a major barrier to AI adoption in healthcare.

Limitations and Future Work

While the results are promising, several challenges remain. The dataset size, though augmented, is relatively limited compared to real-world patient diversity, raising concerns about generalizability. Moreover, complex cases with mixed histologies or rare metastasis patterns may still challenge the system. Future work should focus on:

- 1) Expanding datasets across diverse demographics,
- 2) Exploring multimodal inputs (e.g., PET-CT, clinical biomarkers), and
- 3) Conducting prospective clinical validation to evaluate real-world effectiveness.

6. Conclusion

This study presents a robust deep learning-based framework for the classification of lung cancer using the Tumor–Node–Metastasis (TNM) staging system. By integrating an optimized Conditional Generative Adversarial Network (c-GAN) for automatic segmentation with ResNet50 feature extraction and Support Vector Machine (SVM) classifiers, the proposed system achieves high accuracy in staging CT lung scans. Unlike conventional approaches, this methodology eliminates the need for manual intervention in region-of-interest selection, thereby reducing operator dependency and enhancing reproducibility. The experimental results on the TCIA dataset demonstrate that the proposed system outperforms traditional models such as NMF, UNet, and ResNet in both Dice Similarity Coefficient (DSC) and Jaccard Index (J) metrics, consistently achieving scores above 0.98. These findings confirm the effectiveness of the c-GAN-based segmentation in capturing precise tumor boundaries and improving classification reliability. Moreover, the integration of explainability techniques such as SHAP, LIME, and Grad-CAM adds transparency, allowing clinicians to interpret and validate the model's predictions, which is vital for clinical acceptance. From a pharmacological perspective, accurate TNM classification plays a crucial role in guiding treatment strategies. Early-stage cancers may benefit from targeted therapies, while advanced stages often require systemic chemotherapy, immunotherapy, or combination regimens. The proposed system thus not only improves diagnostic accuracy but also supports the design of patient-specific

therapeutic interventions. While the framework demonstrates strong potential, limitations remain, including the relatively small and homogeneous dataset, which may affect generalizability to diverse populations. Future work should focus on expanding datasets, incorporating multimodal imaging and biomarkers, and validating the system through clinical trials. This research underscores the promise of deep learning in enhancing cancer staging accuracy and its potential to revolutionize precision oncology by enabling timely, reliable, and personalized lung cancer treatment planning.

References

- [1] Pawar SP, Talbar SN. Multi-level deep learning based lung cancer classifier for classification based on the tumour-node-metastasis approach. *Int J Imaging Syst Technol*. 2023; 33(3): 881-894. <https://doi.org/10.1002/ima.22835>.
- [2] Ismaeel, H. K., & Abdulazeez, A. M. (2024). Lung cancer detection and classification based on deep learning: a review. *Jurnal Teknoinfo*, 18(2), 458. <https://doi.org/10.33365/jti.v18i2.4309>.
- [3] Hueman, M. T., Wang, H., Liu, Z., Henson, D. E., Nguyen, C., Park, D., Sheng, L., & Chen, D. (2021). Expanding TNM for lung cancer through machine learning. *Thoracic Cancer*, 12(9), 1423–1430. <https://doi.org/10.1111/1759-7714.13926>.
- [4] Sirisha, J. (2024). Lung cancer prediction through deep learning. *Indian Scientific Journal of Research in Engineering and Management*. <https://doi.org/10.55041/IJSREM29970>.
- [5] Ilani, M. A., Kavei, A., & Tehran, S. M. (2024). Advancing Lung Cancer Classification through Machine Learning: A Comprehensive Comparative Analysis of Model Performance. <https://doi.org/10.20944/preprints202406.0300.v1>.
- [6] A. Iyer, H. Vyshnavi A M, and K. Namboori P K, "Deep Convolution Network Based Prediction Model for Medical Diagnosis of Lung Cancer - A Deep Pharmacogenomic Approach : deep diagnosis for lung cancer," *2018 Second International Conference on Advances in Electronics, Computers and Communications (ICAEECC)*, Bangalore, India, 2018, pp. 1-4, <https://doi.org/10.1109/ICAEECC.2018.8479499>.
- [7] Wang, X., Sharpnack, J., & Lee, T. C. M. (2024). Improving Lung Cancer Diagnosis and Survival Prediction with Deep Learning and CT Imaging. <https://doi.org/10.1371/journal.pone.0323174>.
- [8] Middleton, G., Middleton, G., Fletcher, P., Popat, S., Savage, J., Summers, Y., Greystoke, A., Gilligan, D., Cave, J., O'Rourke, N., Brewster, A., Toy, E., Spicer, J., Jain, P., Dangoor, A., Mackean, M., Forster, M., Farley, A., Wherton, D., ... Billingham, L. (2020). The National Lung Matrix Trial of personalized therapy in lung cancer. *Nature*, 583(7818), 807–812. <https://doi.org/10.1038/s41586-020-2481-8>.
- [9] Nusantara, J., Soesanti, I., & Ardiyanto, I. (2024). Lung Cancer Detection Algorithm and Method Using Deep Learning Techniques: A Systematic Literature Review. 75–80. <https://doi.org/10.1109/ICE3IS62977.2024.10775504>.
- [10] Javed, R., Abbas, T., Khan, A.H. et al. Deep learning for lungs cancer detection: a review. *Artif Intell Rev* 57, 197 (2024). <https://doi.org/10.1007/s10462-024-10807-1>.
- [11] Chandrasekar, T., Karunanithi, P. K., Jenifer, A. E., & Dhiraj, I. (2024). TPLSTM-Based Deep ANN with Feature Matching Prediction of Lung Cancer. 317–328. <https://doi.org/10.1002/9781394175376.ch18>.
- [12] Gayap, H. T., & Akhloufi, M. A. (2024). Deep Machine Learning for Medical Diagnosis, Application to Lung Cancer Detection: A Review. *BioMedInformatics*, 4(1), 236-284. <https://doi.org/10.3390/biomedinformatics4010015>.
- [13] Jagadeesh K, Rajendran A. Lung Tumor Staging and Classification with Machine Learning and Deep Learning Models, 07 March 2024, PREPRINT (Version 1) available at Research Square. <https://doi.org/10.21203/rs.3.rs-3940572/v1>.
- [14] Acharya, B.S., Ramasubramanian, K. (2022). Comparative Analysis of Advanced Machine Learning Based Techniques to Identify the Lung Cancer: A Review. In: Kumar, A., Fister Jr., I., Gupta, P.K., Debayle, J., Zhang, Z.J., Usman, M. (eds) *Artificial Intelligence and Data Science. ICAIDS 2021. Communications in Computer and Information Science*, vol 1673. Springer, Cham. https://doi.org/10.1007/978-3-031-21385-4_1.
- [15] Davri, A., Birbas, E., Kanavos, T., Ntritsos, G., Giannakeas, N., Tzallas, A. T., & Batistatou, A. (2023). Deep Learning for Lung Cancer Diagnosis, Prognosis and Prediction Using Histological and Cytological Images: A Systematic Review. *Cancers*, 15. <https://doi.org/10.3390/cancers15153981>.
- [16] T. M. Kulkarni and A. O. Mulani. Deep Learning Based FaceMask Detection: An Approach to Reduce Pandemic Spreads. *African Journal of Biological Sciences (South Africa)*. 2024; 6(6), 783-795.
- [17] Birajadar Ganesh Basawaraj et al. Epilepsy Identification using Hybrid CoPro-DCNN Classifier. *International Journal of Computing and Digital Systems*. 2024; 16(1): 783-796. <https://doi.org/10.12785/ijcds/160157>.
- [18] Kolhe V. A. et al. Computational and experimental analyses of pressure drop in curved tube structural sections of Coriolis mass flow metre for laminar flow region. *Ships and Offshore Structures*, 2024; 1-10: 1974-1983. <https://doi.org/10.1080/17445302.2024.2317651>.
- [19] Mulani A. O., Birajadar G., Ivković, N., Salah B., & Darlis A. R. Deep learning based detection of dermatological diseases using convolutional neural networks and decision trees. *Traitement du Signal*, 2023; 40(6): 2819-2825. <https://doi.org/10.18280/ts.400642>.
- [20] Mane P. B. & Mulani A. O. High throughput and area efficient FPGA implementation of AES algorithm. *International Journal of Engineering and Advanced Technology*, 2019; 8(4): 519-523.
- [21] Mulani, A. O., & Mane, P. B. (2017). Watermarking and cryptography based image authentication on reconfigurable platform. *Bulletin of Electrical Engineering and Informatics*, 6(2), 181-187. <https://doi.org/10.11591/eei.v6i2.651>.
- [22] Deshpande, H. S., Karande, K. J., & Mulani, A. O. (2014, April). Efficient implementation of AES algorithm on FPGA. In *2014 International Conference on Communication and Signal Processing* (pp. 1895-1899). IEEE. <https://doi.org/10.1109/ICCSP.2014.6950174>.
- [23] Swami, S. S., & Mulani, A. O. (2017, August). An efficient FPGA implementation of discrete wavelet transform for image compression. In *2017 International Conference on Energy, Communication, Data Analytics and Soft Computing (ICECDS)* (pp. 3385-3389). IEEE. <https://doi.org/10.1109/ICECDS.2017.8390088>.
- [24] Kashid, M. M., Karande, K. J., & Mulani, A. O. (2022, November). IoT-based environmental parameter monitoring using machine learning approach. In *Proceedings of the International Conference on Cognitive and Intelligent Computing: ICCIC 2021, Volume 1* (pp. 43-51). Singapore: Springer Nature Singapore. https://doi.org/10.1007/978-981-19-2350-0_5.
- [25] Mulani, A. O., & Mane, P. B. (2016). Area efficient high speed FPGA based invisible watermarking for image authentication. *Indian journal of Science and Technology*, 9(39), 1-6. <https://doi.org/10.17485/ijst/2016/v9i39/101888>.
- [26] Kulkarni, P. R., Mulani, A. O., & Mane, P. B. (2016). Robust invisible watermarking for image authentication. In *Emerging Trends in Electrical, Communications and Information Technologies: Proceedings of ICECIT-2015* (pp. 193-200). Singapore: Springer Singapore. https://doi.org/10.1007/978-981-10-1540-3_20.
- [27] Mulani, A. O., Jadhav, M. M., & Seth, M. (2022). Painless Non-invasive blood glucose concentration level estimation using PCA and machine learning. The CRC Book entitled *Artificial Intelligence, Internet of Things (IoT) and Smart Materials for Energy Applications*.
- [28] Mulani, A. O., & Mane, P. (2018). Secure and area efficient implementation of digital image watermarking on reconfigurable platform. *International Journal of Innovative Technology and Exploring Engineering*, 8(2), 56-61.
- [29] Jadhav, H. M., Mulani, A., & Jadhav, M. M. (2022). Design and development of chatbot based on reinforcement learning. *Machine Learning Algorithms for Signal and Image Processing*, 219-229. <https://doi.org/10.1002/9781119861850.ch12>.
- [30] Mulani, A. O., Sardey, M. P., Kinage, K., Salunkhe, S. S., Fegade, T., & Fegade, P. G. (2025). ML-powered Internet of Medical Things (MLIOMT) structure for heart disease prediction. *Journal of Pharmacology and Pharmacotherapeutics*, 16(1), 38-45. <https://doi.org/10.1177/0976500X241281490>.
- [31] Saurabh Singh, Karm Veer Arya, Ciro Rodriguez Rodriguez, Altaf Osman Mulani, (2025), *Emerging Trends in Artificial Intelligence, Data Science and Signal Processing, Communications in Computer and Information Science, Volume I*. <https://doi.org/10.1007/978-3-031-88762-8>.

- [32] Saurabh Singh, Karm Veer Arya, Ciro Rodriguez Rodriguez, Altaf Osman Mulani, (2025), Emerging Trends in Artificial Intelligence, Data Science and Signal Processing, Communications in Computer and Information Science, Volume II. <https://doi.org/10.1007/978-3-031-88762-8>.
- [33] Mulani, A.O., Kulkarni, T.M. (2025). Face Mask Detection System Using Deep Learning: A Comprehensive Survey. In: Singh, S., Arya, K.V., Rodriguez, C.R., Mulani, A.O. (eds) Emerging Trends in Artificial Intelligence, Data Science and Signal Processing. AIDSP 2023. Communications in Computer and Information Science, vol 2439. Springer, Cham. https://doi.org/10.1007/978-3-031-88759-8_3.
- [34] Karve, S., Gangonda, S., Birajadar, G., Godase, V., Ghodake, R., Mulani, A.O. (2025). Optimized Neural Network for Prediction of Neurological Disorders. In: Singh, S., Arya, K.V., Rodriguez, C.R., Mulani, A.O. (eds) Emerging Trends in Artificial Intelligence, Data Science and Signal Processing. AIDSP 2023. Communications in Computer and Information Science, vol 2440. Springer, Cham. https://doi.org/10.1007/978-3-031-88762-8_18.